The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.
LaFleur, K. & Nemec, E. (2019). What is the role of cannabidol in refractory epilepsy. Journal of the American Academy of PAs, 32(3), 16-18. Doi: 10.1097/01.JAA.0000553393.36249.df